Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

Neoadjuvant SHR-A1811 showed similar pathologic complete response rates to the standard 4-drug regimen in patients with ...

The MARGOT/TBCRC052 trial didn't show improvement in pathologic complete response rates with margetuximab for early-stage HER2-positive breast cancer.

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Medical Dialogues team earlier reported that the company had received approval from the Subject Expert Committee SEC, which is functional under the Central Drug Standard Control Organisation (CDSCO) ...

The DAPHNe trial (NCT03716180) showed that circulating tumor DNA (ctDNA) is a promising biomarker for monitoring treatment response and minimal residual disease (MRD) in early-stage HER2-positive ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Subcutaneous administration ...

New Delhi: Zydus Lifsciences has got approval from the Subject Expert Committee SEC functional under the Central Drug Standard Control Organisation (CDSCO) for a phase IV study to evaluate the safety ...

“Early administration of this combination may eliminate the need for polychemotherapy, minimize toxicity, and improve long-term outcomes for patients with early stage, HER2-positive breast ...